Debbie Louise Phinney, OTR, LPC | |
1430 Wilkins Cir, Casper, WY 82601-1336 | |
(307) 237-9583 | |
(307) 265-7277 |
Full Name | Debbie Louise Phinney |
---|---|
Gender | Female |
Speciality | Counselor |
Location | 1430 Wilkins Cir, Casper, Wyoming |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1316084452 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225XP0200X | Occupational Therapist - Pediatrics | OTR-453 (Wyoming) | Secondary |
101Y00000X | Counselor | LPC 1337 (Wyoming) | Primary |
Mailing Address | Practice Location Address |
---|---|
Debbie Louise Phinney, OTR, LPC 1430 Wilkins Cir, Casper, WY 82601-1336 Ph: (307) 237-9583 | Debbie Louise Phinney, OTR, LPC 1430 Wilkins Cir, Casper, WY 82601-1336 Ph: (307) 237-9583 |
News Archive
Do not smoke and do not allow yourself to be exposed to smoke because second-hand smoke and third-hand smoke are just as deadly as first-hand smoke, says a scientist at the University of California, Riverside who, along with colleagues, conducted the first animal study of the effects of third-hand smoke.
Funding cuts to Ontario pharmacists would have a devastating effect on patients, particularly those cared for by independent pharmacists, Janet McCutchon, vice-chair of the Board of Directors of the Ontario Pharmacists' Association, told the Economic Club of Canada yesterday.
Pharmaceutical Research and Manufacturers of America President and CEO Billy Tauzin today honored Ron and Raychel Bartek for their dedicated work driving awareness of Friedreich's ataxia, a debilitating, life-threatening, rare disease.
Forest Laboratories, Inc. (NYSE: FRX) and Glenmark Pharmaceuticals S.A. (Switzerland), a wholly owned subsidiary of Glenmark Pharmaceuticals India (GPL) today announced top-line results from a Phase IIb dose range-finding study of oglemilast in patients with Chronic Obstructive Pulmonary Disease (COPD). Once-daily treatment with oglemilast did not show a statistically meaningful increase from baseline compared to placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in patients with COPD. Oglemilast was well tolerated at all doses studied.
› Verified 5 days ago